A Phase 1 Study to Assess Pharmacokinetics (PK) and Safety of Ixazomib, an Oral Proteasome Inhibitor, in Patients with Moderate or Severe Hepatic Impairment
- Resource Type
- Abstract
- Source
- In
Blood 3 December 2015 126(23):3032-3032 - Subject
- Language
- ISSN
- 0006-4971